Seeking Genetically-Based Early Discovery Research in Nephrology

BioMarin Pharmaceutical Inc. is a world leader in developing and commercialising first- or best-in-class therapies for rare genetic diseases. BioMarin Pharmaceutical Inc. is looking for early discovery research that involve targets with strong genetic evidence in the area of kidney disease, with a focus on Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Alport Syndrome.

Approaches of Interest

- Therapeutic approaches to treat ADPKD, X-linked Alport Syndrome, or all subtypes of Alport Syndrome treated with the same therapeutic approach
- Unique therapeutic modalities are encouraged
- Novel approaches for targeted delivery to the kidney, including adeno-associated virus (AAV) capsids, small molecules, oligonucleotides and drug conjugates for podocyte or distal tubule/collection duct cell delivery
- Effective or novel routes of administration to podocytes or distal tubule/collection duct cells for the following modalities: AAV, oligonucleotides, small molecules, proteins, and lipid nanoparticles

Developmental Stages of Interest

- Opportunities at basic research phase to Phase I clinical trial are within scope
- Opportunities with in vivo validation are of highest interest, although opportunities with in vitro validation will still be considered

Submission Information

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g. relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

BioMarin Pharmaceutical Inc. is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations. BioMarin Pharmaceutical Inc. is looking to establish long-standing partnerships in the field of nephrology.

Opportunities sought

- Spinout companies
- Research projects
- Centres of excellence
- Academics and expertise
- Technologies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: 15th November 2021 - 11:59 pm GMT

Have any questions?
Contact our team at discover@in-part.co.uk

© 2021 IN-PART All rights reserved

BioMarin Pharmaceutical take pride in going where the science leads them, pioneering breakthrough treatments for debilitating and life-threatening conditions where they can significantly improve upon the current standard of care.